Barclays PLC Bellus Health Inc. Transaction History

Barclays PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	SELL	$0.0 - $14.75 $0 - $4.08 Million	-276,571 Reduced 78.34%	76,450 $1.13 Million
Q1 2023 May 04, 2023	BUY	$7.14 - $8.53 $512,859 - $612,701	71,829 Added 25.54%	353,021 $2.54 Million
Q4 2022 Feb 13, 2023	BUY	$8.22 - $10.76 $343,497 - $449,638	41,788 Added 17.46%	281,192 $2.31 Million
Q3 2022 Nov 03, 2022	SELL	$8.95 - $12.0 $102,029 - $136,800	-11,400 Reduced 4.55%	239,404 $2.53 Million
Q2 2022 Aug 12, 2022	SELL	$6.46 - $10.02 $323,071 - $501,110	-50,011 Reduced 16.63%	250,804 $2.32 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $1.67 Million - $2.4 Million	300,815 New	300,815 $2.07 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.